A Ten-Year Analysis of Receptor Variability and Phenotypic Changes in Metastatic Breast Cancer: Insights from a Retrospective Study of 363 Cases at a Single Institution - Summary - MDSpire
Advertisement
A Ten-Year Analysis of Receptor Variability and Phenotypic Changes in Metastatic Breast Cancer: Insights from a Retrospective Study of 363 Cases at a Single Institution
To investigate changes in the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and their molecular subtypes in primary and metastatic breast cancer, and their impact on prognosis.
Key Findings:
Receptor discordance rates were 25.1% for ER, 33.3% for PR, 32.8% for HER2, and 33.8% for molecular subtypes.
PR showed the highest discordance, often transitioning from positive to negative.
HER2 discordance was highest in liver metastases (59.3%).
Loss of HR or HER2 expression correlated with poorer overall survival.
Sustained or acquired HR/HER2 positivity improved overall survival.
Interpretation:
Heterogeneity in receptor expression significantly influences prognosis and treatment outcomes in metastatic breast cancer, highlighting the necessity for reassessment of receptor status in metastatic lesions.
Limitations:
Retrospective design may introduce selection bias, potentially affecting the validity of results.
Single-institution study limits generalizability.
Conclusion:
Reassessment of receptor status in metastatic lesions is crucial for optimizing individualized treatment strategies and enhancing patient outcomes.
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 - 30.
